- Home
- NKTR vs OPP Comparison
NKTR vs OPP Comparison
Compare NKTR & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- OPP
- Stock Information
- Founded
- NKTR 1990
- OPP 2010
- Country
- NKTR United States
- OPP United States
- Employees
- NKTR N/A
- OPP N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- OPP Finance/Investors Services
- Sector
- NKTR Health Care
- OPP Finance
- Exchange
- NKTR Nasdaq
- OPP Nasdaq
- Market Cap
- NKTR 247.9M
- OPP 200.8M
- IPO Year
- NKTR 1994
- OPP N/A
- Fundamental
- Price
- NKTR $0.90
- OPP $8.40
- Analyst Decision
- NKTR Strong Buy
- OPP
- Analyst Count
- NKTR 5
- OPP 0
- Target Price
- NKTR $4.50
- OPP N/A
- AVG Volume (30 Days)
- NKTR 1.5M
- OPP 108.0K
- Earning Date
- NKTR 03-03-2025
- OPP 01-01-0001
- Dividend Yield
- NKTR N/A
- OPP 14.41%
- EPS Growth
- NKTR N/A
- OPP N/A
- EPS
- NKTR N/A
- OPP N/A
- Revenue
- NKTR $93,137,000.00
- OPP N/A
- Revenue This Year
- NKTR $12.85
- OPP N/A
- Revenue Next Year
- NKTR N/A
- OPP N/A
- P/E Ratio
- NKTR N/A
- OPP N/A
- Revenue Growth
- NKTR 5.53
- OPP N/A
- 52 Week Low
- NKTR $0.50
- OPP $7.26
- 52 Week High
- NKTR $1.93
- OPP $8.83
- Technical
- Relative Strength Index (RSI)
- NKTR 40.16
- OPP 49.56
- Support Level
- NKTR $0.87
- OPP $8.29
- Resistance Level
- NKTR $0.94
- OPP $8.60
- Average True Range (ATR)
- NKTR 0.09
- OPP 0.12
- MACD
- NKTR -0.01
- OPP 0.00
- Stochastic Oscillator
- NKTR 15.63
- OPP 42.86
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.